| Stereochemistry | ACHIRAL |
| Molecular Formula | C15H21N3O2S.2ClH |
| Molecular Weight | 380.333 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.Cl.CCOC1=CC=C2N=C(NC2=C1)SCCN3CCOCC3
InChI
InChIKey=OFMVMQZFMVQDFO-UHFFFAOYSA-N
InChI=1S/C15H21N3O2S.2ClH/c1-2-20-12-3-4-13-14(11-12)17-15(16-13)21-10-7-18-5-8-19-9-6-18;;/h3-4,11H,2,5-10H2,1H3,(H,16,17);2*1H
Fabomotizole (also known as Afobazole) is a selective non-benzodiazepine anxiolytic which was developed in Russia and launched in 2006. The drug is used for the treatment of wide range of diseases: generalized anxious disorders, neurasthenia, adaptation disorders, sleep disorders, for alleviation of withdrawal syndrome. According to the drug label (in Russian), its action is related to the interaction with sigma-1 receptors.
CNS Activity
Approval Year
Doses
AEs
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as perpetrator
Drug as victim
PubMed
Patents
Sample Use Guides
For adult persons and children it is recommended to use internally, after meal. Usually it is recommended to use 1 tablet (10 mg) trice per day. The maximum daily dose is 60 mg. The period of therapy is 2-4 weeks. According to doctor prescription it is possible to prolong the period up to 3 months.
Route of Administration:
Oral
ACTIVE MOIETY
SUBSTANCE RECORD
